Patheon Inc (TSX:PTI), a provider of drug development and manufacturing services, has agreed to be taken private in a deal that values the company at around US$1.4 billion.

Contacts. Patheon For investors: Tyler Gronbach, +1-919-226-3201 Vice President, Investor Relations, Corporate Communications or For media: Mari Mansfield, +1-919-226-3137 Senior Director ...

Patheon, a business unit of DPx Holdings B.V., delivers a combination of unrivaled quality, reliability and compliance, with a reputation for scientific and technical excellence to customers in ...

Patheon, a leading global provider of high-quality drug development and delivery solutions to the pharmaceutical and biopharma industries, today unveiled its new brand identity, reflecting the ...

Patheon, which has 1200 employees at its Greenville plant, is being bought by Thermo Fisher Scientific, the companies announced today. Thermo Fisher will pay $7.2 billion for Patheon, which is a U ...

With Patheon's shares trading within $0.50 of the buyout price, it probably makes sense for shareholders to take a victory lap and hit the sell button.

Shares of Patheon NV, a JLL Partners-backed provider of outsourced pharmaceutical development and manufacturing services, traded at $24.29 late Thursday morning after the company on Wednesday ...

Patheon has announced that it has signed a strategic agreement with Grünenthal to serve as its preferred development partner for its products made using Grünenthal’s innovative abuse deterrent ...

NewCo would have combined annual sales of $2 billion, and be 51% owned by private-equity firm JLL Partners, with the remainder owned by DSM. JLL, which owns 55.7% of Patheon stock, will contribute ...

Patheon will host a conference call and live internet webcast, along with a slide presentation on Monday, October 29, 2012 at 8:30 a.m. ET to discuss the transaction.

Patheon said in its recent SEC-1 that it will use the cash to repay all of its outstanding $550 million of Senior PIK toggle notes, pay-related fees, expenses and accrued interest.

Patheon, which bought Agere Pharmaceuticals in March, plans to increase revenue from its Bend unit by 40 percent in the coming year, according to the summary. The company also plans to invest $5.7 ...